SIGA Technologies Valuation
Is SIGA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SIGA?
Other financial metrics that can be useful for relative valuation.
| What is SIGA's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$533.81m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2x |
| Enterprise Value/EBITDA | 3.1x |
| PEG Ratio | -0.2x |
Price to Earnings Ratio vs Peers
How does SIGA's PE Ratio compare to its peers?
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 24.9x | ||
PROC Procaps Group | 7.8x | 2.5% | US$468.2m |
AVIR Atea Pharmaceuticals | 10.5x | -8.3% | US$375.6m |
PAHC Phibro Animal Health | 14.2x | 13.8% | US$658.6m |
MRMD MariMed | 67.3x | n/a | US$148.5m |
SIGA SIGA Technologies | 4.9x | -20.3% | US$533.8m |
Price to Earnings Ratio vs Industry
How does SIGA's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price to Earnings Ratio vs Fair Ratio
What is SIGA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 4.9x |
| Fair PE Ratio | 7.2x |
Price-To-Earnings vs Fair Ratio: SIGA is good value based on its Price-To-Earnings Ratio (4.9x) compared to the estimated Fair Price-To-Earnings Ratio (7.2x).
Share Price vs Fair Value
What is the Fair Price of SIGA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?